Free Trial

Chase Investment Counsel Corp Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals logo with Medical background
Remove Ads

Chase Investment Counsel Corp acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 54,000 shares of the biopharmaceutical company's stock, valued at approximately $1,126,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Proficio Capital Partners LLC bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at about $339,000. Oppenheimer & Co. Inc. increased its position in shares of Catalyst Pharmaceuticals by 28.3% during the fourth quarter. Oppenheimer & Co. Inc. now owns 104,487 shares of the biopharmaceutical company's stock worth $2,181,000 after acquiring an additional 23,078 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Catalyst Pharmaceuticals by 1.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 204,024 shares of the biopharmaceutical company's stock valued at $4,258,000 after acquiring an additional 3,742 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Catalyst Pharmaceuticals by 1.3% in the fourth quarter. Bank of New York Mellon Corp now owns 723,545 shares of the biopharmaceutical company's stock worth $15,100,000 after purchasing an additional 9,194 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Catalyst Pharmaceuticals during the 4th quarter worth $581,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ:CPRX traded down $0.21 on Wednesday, hitting $21.89. 993,205 shares of the company were exchanged, compared to its average volume of 1,271,383. The firm has a market capitalization of $2.66 billion, a P/E ratio of 18.55, a price-to-earnings-growth ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $24.64. The stock's 50 day moving average price is $22.27 and its 200 day moving average price is $21.49.

Remove Ads

Analyst Ratings Changes

CPRX has been the topic of several research reports. Robert W. Baird lifted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Finally, Bank of America reiterated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and an average target price of $32.50.

View Our Latest Report on CPRX

Insiders Place Their Bets

In related news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares of the company's stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Profile

(Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

See Also

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Should You Invest $1,000 in Catalyst Pharmaceuticals Right Now?

Before you consider Catalyst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.

While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads